diridavumab
mAbexperimental
Diridavumab (CR6261) (INN) is a monoclonal antibody designed for the treatment of influenza A. — Wikipedia
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2013 (NCT01406418)
Timeline
Indications
Mechanism of action
- HemagglutininINHIBITOR
HA inhibitor
- Influenza virusImmunity, passive
Influenza virus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDiridavumab ↗
- ChEMBLCHEMBL3137350 ↗
- ChEMBLCHEMBL2109618 ↗
Also known as
- cr6261
- cr6261
- cr-6261
- diridavumab
- diridavumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02371668 | Phase 2 | Jan 14, 2015 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01992276 | Phase 2 | Dec 1, 2013 | Crucell, National Institutes of Health (NIH) |
| NCT02016066 | Phase 1 | Dec 1, 2013 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01406418 | Phase 1 | Feb 1, 2013 | Crucell, IQVIA, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Crucell | For profit | 2 | 2 | 2 | 2013 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 1 | 2 | 2013 |
| IQVIA | For profit | 1 | 0 | 1 | 2013 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2013 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2013 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2013 |
6 organizations
Page 1 / 1